Ultradeformable liposomal delivery of vismodegib modulates its biological activity in melanoma cells
IntroductionVismodegib (VDG), a Smoothened inhibitor approved for basal cell carcinoma, has potential for repurposing in other tumors in which Hedgehog (Hh) signaling contributes to malignancy. However, systemic VDG treatment is associated with relevant adverse effects, and its effective delivery to...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2026-06-01
|
| Collection: | Frontiers in Medical Technology |
| Sujets: | |
| Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fmedt.2026.1826970/full |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|